Market Overview

ICYMI: Epizyme, MoviePass, And A Bull Call On Novavax

ICYMI: Epizyme, MoviePass, And A Bull Call On Novavax
Related EPZM
The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results
The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price
Epizyme Inc. (EPZM) CEO Rob Bazemore on Q3 2018 Results - Earnings Call Transcript (Seeking Alpha)
Related HMNY
56 Biggest Movers From Yesterday
Mid-Afternoon Market Update: Crude Oil Down Over 4%; Therapix Biosciences Shares Spike Higher
Helios and Matheson Analytics reports Q3 results (Seeking Alpha)

In case you missed it, here are some of Benzinga's top stories from Wednesday, Jan. 10, 2018.

Novavax Back In Favor

Shares of Novavax, Inc (NASDAQ: NVAX) got a heavy dose of upside when a bullish analyst from B. Riley FBR indicated he sees potential for the stock to trade 400 percent higher over the next 12 months. Jayson Derrick reports.


Helios and Matheson Analytics Inc (NASDAQ: HMNY) CEO in a recent interview admitted to being open to the notion of an initial coin offering for MoviePass, the movie subscription service his company is heavily invested in. To learn more, check out Wayne Duggan’s “Helios And Matheson Investors Are Loving The MoviePass ICO Talk.”

Epizyme Has Potential

Holders of Epizyme, Inc (NASDAQ: EPZM) stock saw their investment validated today by Morgan Stanley’s initiation of coverage with an Overweight rating. Get the details of the thesis in Shanthi Rexaline’s “Morgan Stanley: Epizyme Has 'Blockbuster' Cancer Drug In The Making.”

Latest Ratings for EPZM

Nov 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Sep 2018Leerink SwannInitiates Coverage OnMarket Perform
Sep 2018Morgan StanleyReinstatesEqual-Weight

View More Analyst Ratings for EPZM
View the Latest Analyst Ratings

Posted-In: BZ ICYMIAnalyst Color News Previews After-Hours Center Analyst Ratings Media Trading Ideas Best of Benzinga


Related Articles (HMNY + EPZM)

View Comments and Join the Discussion!

Latest Ratings

CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Earnings Scheduled For January 11, 2018

7 Stocks Moving In Wednesday's After-Hours Session